FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783175942> ?p ?o ?g. }

• W2783175942 endingPage "725" @default.
• W2783175942 startingPage "725" @default.
• W2783175942 abstract "Abstract BACKGROUND: Recurrent isocitrate dehydrogenase (IDH) 1 mutations are observed in 6-10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120), a potent, selective, oral, small-molecule inhibitor of the mutant IDH1 (mIDH1) protein, is a promising therapeutic candidate for the treatment of patients with mIDH1 AML. Through inhibition of mIDH1, ivosidenib suppresses the abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to clinical responses via differentiation of malignant cells. AIM: To report safety and efficacy data from the first-in-human phase 1 study of ivosidenib in patients with mIDH1 advanced hematologic malignancies including relapsed/refractory (R/R) AML (NCT02074839). This is the first report of data from the 4 expansion cohorts, with a total of 258 patients treated on study. METHODS: The ongoing phase 1 study assesses the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and clinical activity of ivosidenib in mIDH1 hematologic malignancies. Enrollment was completed on May 8, 2017. During dose escalation, patients received ivosidenib as a single agent orally once daily (QD) or twice daily (BID) in 28-day cycles. The MTD was not reached and 500 mg QD was selected as the recommended dose to be tested in 4 expansion cohorts: R/R AML (Arms 1 and 4, where Arm 1 patients are those with relapse after transplantation, second or later relapse, resistance to initial induction or reinduction treatment, or relapse within 1 year of initial treatment, and Arm 4 patients have R/R AML but are not eligible for Arm 1); untreated AML (Arm 2); and other advanced hematologic malignancies including myelodysplastic syndrome (MDS) (Arm 3). Updated safety data will be presented for all patients. Efficacy outcomes will be presented for all R/R AML patients treated at 500 mg QD across the dose escalation and expansion cohorts who received their first dose of ivosidenib at least 6 months prior to the analysis cut-off date of May 12, 2017, as well as for the poorest prognosis Arm 1 subset. Efficacy data for all treated patients from the other expansion cohorts (untreated AML and other advanced hematologic malignancies including MDS) will also be presented. RESULTS: In all, 258 patients (78 in dose escalation, 180 in expansion) were treated with ivosidenib. As of May 12, 2017, 62 of 258 (24%) patients were continuing on treatment. The median duration of exposure to ivosidenib was 3.5 months (range 0.1-33.5). Twenty-two (8.5%) patients discontinued treatment to proceed to allogeneic stem cell transplantation. Treatment was well tolerated; the most common adverse events (AEs) (n=258) of any grade irrespective of causality occurring in ≥20% of patients were diarrhea (33%), leukocytosis (30%), nausea (30%), fatigue (29%), febrile neutropenia (25%), dyspnea (24%), anemia (23%), QT prolongation (23%), peripheral edema (22%), pyrexia (21%), and decreased appetite (20%). The majority of these AEs were grades 1-2 and reported as unrelated to treatment. Differentiation syndrome (DS) was observed in 29 of 258 (11.2%) patients, including grade ≥3 DS in 14 (5.4%); study drug was held owing to DS in 11 patients (4.3%), and no instances of DS led to permanent treatment discontinuation or death. The primary efficacy endpoint for R/R AML is the CR+CRh rate, i.e., the rate of complete remission (CR according to modified IWG 2003 criteria plus CR with partial hematologic recovery, defined as CR except absolute neutrophil count &gt;0.5 × 109/L [500/µL] and platelet count &gt;50 × 109/L [50,000/µL]). Among 125 Arm 1 R/R AML patients receiving ivosidenib 500 mg QD across dose escalation and expansion who received their first dose at least 6 months prior to the analysis cutoff date, the CR+CRh rate was 30.4% (95% CI 22.5%, 39.3%), including CR in 27 (21.6%) and CRh in 11 (8.8%) patients. Median duration of CR+CRh was 8.2 months (95% CI 5.5, 12.0), and duration of CR was 9.3 months (95% CI 5.6, 18.3). The overall response rate (CR+CRi/CRp+PR+MLFS) was 41.6% (95% CI 32.9%, 50.8%) (52/125 patients). CONCLUSION: Ivosidenib monotherapy is well tolerated in patients with mIDH1 AML and other advanced hematologic malignancies. In a high-risk, molecularly defined R/R AML patient population with unmet medical need, ivosidenib induced durable remissions and improved patient outcomes. These findings support the role of ivosidenib as an effective, oral, targeted treatment for patients with mIDH1 AML. Disclosures DiNardo: Celgene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Daiichi-Sankyo: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. De Botton: Pfizer: Honoraria; Novartis: Honoraria; Celgene: Honoraria; Servier: Honoraria; Agios: Honoraria, Research Funding. Stein: GSK: Other: Advisory Board, Research Funding; Constellation Pharma: Research Funding; Seattle Genetics: Research Funding; Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Celgene Corporation: Consultancy, Other: Travel expenses, Research Funding; Pfizer: Consultancy, Other: Travel expenses; Novartis: Consultancy, Research Funding. Roboz: AbbVie, Agios, Amgen, Amphivena, Array Biopharma Inc., Astex, AstraZeneca, Celator, Celgene, Clovis Oncology, CTI BioPharma, Genoptix, Immune Pharmaceuticals, Janssen Pharmaceuticals, Juno, MedImmune, MEI Pharma, Novartis, Onconova, Pfizer, Roche Pharmace: Consultancy; Cellectis: Research Funding. Mims: Novartis: Honoraria. Pollyea: Takeda, Ariad, Alexion, Celgene, Pfizer, Pharmacyclics, Gilead, Jazz, Servier, Curis: Membership on an entity's Board of Directors or advisory committees; Agios, Pfizer: Research Funding. Altman: Syros: Consultancy; NCCN: Other: Educational speaker; BMS: Consultancy; Celgene: Consultancy; Astellas: Consultancy; Ceplene: Consultancy; Janssen Pharmaceuticals: Consultancy; Novartis: Consultancy; ASH: Other: Educational speaker. Collins: Celgene Corporation: Research Funding; Agios: Research Funding; Arog: Research Funding; BMS: Research Funding. Mannis: Curis: Honoraria; Juno: Research Funding; Agios: Research Funding; Amgen: Honoraria. Uy: GlycoMimetics: Consultancy; Novartis: Consultancy, Other: Travel Suppport; Boehringer Ingelheim: Consultancy. Fathi: Juno: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; Agios: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Medimmune: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Stein: Amgen: Consultancy, Speakers Bureau; Stemline: Consultancy. Erba: Celgene: Consultancy, Other: Chair, Scientific Steering Committee , Speakers Bureau; Incyte: all research support paid to University of Alabama, Consultancy, Speakers Bureau; Jazz: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Amgen: Consultancy, Other: all research support paid to University of Alabama, Research Funding; Daiichi Sankyo: Consultancy, Other: all research support paid to University of Alabama, Research Funding; ImmunoGen: Consultancy, Other: all research support paid to University of Alabama, Research Funding; MacroGen: Consultancy; Ono: Consultancy; Pfizer: Consultancy; Seattle Genetics: Consultancy, Other: all research support paid to University of Alabama, Research Funding; Sunesis: Consultancy; Millennium/Takeda: Consultancy, Other: all research support paid to University of Alabama, Research Funding; Agios: Other: all research support paid to University of Alabama, Research Funding; Juno: Other: all research support paid to University of Alabama, Research Funding; Astellas: Other: all research support paid to University of Alabama, Research Funding; Celator: Other: all research support paid to University of Alabama, Research Funding; Janssen: Other: all research support paid to University of Alabama, Research Funding; Glycomimetics: Other: Chair, Data and Safety Monitoring Committee. Traer: ImmunoGen: Consultancy; Tolero: Consultancy; Notable Labs: Equity Ownership. Stuart: Pharmacyclics LLC, an AbbVie Company: Research Funding; Amgen: Consultancy, Honoraria; Agios: Research Funding; Celator/Jazz: Research Funding; Sunesis: Consultancy, Honoraria, Other: Travel Support, Research Funding; Bayer: Research Funding; Novartis: Research Funding; Incyte: Research Funding; ONO: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Research Funding; MedImmune: Research Funding; Cantex: Research Funding; Astellas: Research Funding. Arellano: Cephalon Oncology: Research Funding. Sekeres: Celgene: Membership on an entity's Board of Directors or advisory committees. Yen: Agios: Employment, Equity Ownership. Kapsalis: Agios: Employment, Equity Ownership. Liu: Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Goldwasser: Agios: Employment, Equity Ownership. Agresta: Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Attar: Agios: Employment, Equity Ownership. Stone: Novartis: Consultancy; Celgene: Consultancy; Amgen: Consultancy; Abbvie: Consultancy; Fuji Film: Consultancy; Jazz: Consultancy; Astellas: Consultancy; Pfizer: Consultancy; Arog: Consultancy; Ono: Consultancy; Agios: Consultancy; Sumitomo: Consultancy. Kantarjian: ARIAD: Research Funding; Bristol-Meyers Squibb: Research Funding; Delta-Fly Pharma: Research Funding; Amgen: Research Funding; Pfizer: Research Funding; Novartis: Research Funding." @default.
• W2783175942 created "2018-01-26" @default.
• W2783175942 creator A5001124933 @default.
• W2783175942 creator A5002656825 @default.
• W2783175942 creator A5003572390 @default.
• W2783175942 creator A5003966906 @default.
• W2783175942 creator A5005105433 @default.
• W2783175942 creator A5009684277 @default.
• W2783175942 creator A5010057352 @default.
• W2783175942 creator A5010786159 @default.
• W2783175942 creator A5012863731 @default.
• W2783175942 creator A5014892222 @default.
• W2783175942 creator A5015493242 @default.
• W2783175942 creator A5017435311 @default.
• W2783175942 creator A5020684790 @default.
• W2783175942 creator A5023917898 @default.
• W2783175942 creator A5025780450 @default.
• W2783175942 creator A5032549755 @default.
• W2783175942 creator A5032988049 @default.
• W2783175942 creator A5035051206 @default.
• W2783175942 creator A5039774247 @default.
• W2783175942 creator A5046198086 @default.
• W2783175942 creator A5048185910 @default.
• W2783175942 creator A5050556099 @default.
• W2783175942 creator A5053897548 @default.
• W2783175942 creator A5055740968 @default.
• W2783175942 creator A5063673381 @default.
• W2783175942 creator A5066934816 @default.
• W2783175942 creator A5069675791 @default.
• W2783175942 creator A5071023119 @default.
• W2783175942 creator A5085672843 @default.
• W2783175942 creator A5089074892 @default.
• W2783175942 creator A5089274301 @default.
• W2783175942 creator A5090435894 @default.
• W2783175942 date "2017-12-07" @default.
• W2783175942 modified "2023-10-01" @default.
• W2783175942 title "Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study" @default.
• W2783175942 doi "https://doi.org/10.1182/blood.v130.suppl_1.725.725" @default.
• W2783175942 hasPublicationYear "2017" @default.
• W2783175942 type Work @default.
• W2783175942 sameAs 2783175942 @default.
• W2783175942 citedByCount "12" @default.
• W2783175942 countsByYear W27831759422018 @default.
• W2783175942 countsByYear W27831759422019 @default.
• W2783175942 countsByYear W27831759422020 @default.
• W2783175942 countsByYear W27831759422021 @default.
• W2783175942 crossrefType "journal-article" @default.
• W2783175942 hasAuthorship W2783175942A5001124933 @default.
• W2783175942 hasAuthorship W2783175942A5002656825 @default.
• W2783175942 hasAuthorship W2783175942A5003572390 @default.
• W2783175942 hasAuthorship W2783175942A5003966906 @default.
• W2783175942 hasAuthorship W2783175942A5005105433 @default.
• W2783175942 hasAuthorship W2783175942A5009684277 @default.
• W2783175942 hasAuthorship W2783175942A5010057352 @default.
• W2783175942 hasAuthorship W2783175942A5010786159 @default.
• W2783175942 hasAuthorship W2783175942A5012863731 @default.
• W2783175942 hasAuthorship W2783175942A5014892222 @default.
• W2783175942 hasAuthorship W2783175942A5015493242 @default.
• W2783175942 hasAuthorship W2783175942A5017435311 @default.
• W2783175942 hasAuthorship W2783175942A5020684790 @default.
• W2783175942 hasAuthorship W2783175942A5023917898 @default.
• W2783175942 hasAuthorship W2783175942A5025780450 @default.
• W2783175942 hasAuthorship W2783175942A5032549755 @default.
• W2783175942 hasAuthorship W2783175942A5032988049 @default.
• W2783175942 hasAuthorship W2783175942A5035051206 @default.
• W2783175942 hasAuthorship W2783175942A5039774247 @default.
• W2783175942 hasAuthorship W2783175942A5046198086 @default.
• W2783175942 hasAuthorship W2783175942A5048185910 @default.
• W2783175942 hasAuthorship W2783175942A5050556099 @default.
• W2783175942 hasAuthorship W2783175942A5053897548 @default.
• W2783175942 hasAuthorship W2783175942A5055740968 @default.
• W2783175942 hasAuthorship W2783175942A5063673381 @default.
• W2783175942 hasAuthorship W2783175942A5066934816 @default.
• W2783175942 hasAuthorship W2783175942A5069675791 @default.
• W2783175942 hasAuthorship W2783175942A5071023119 @default.
• W2783175942 hasAuthorship W2783175942A5085672843 @default.
• W2783175942 hasAuthorship W2783175942A5089074892 @default.
• W2783175942 hasAuthorship W2783175942A5089274301 @default.
• W2783175942 hasAuthorship W2783175942A5090435894 @default.
• W2783175942 hasConcept C104317684 @default.
• W2783175942 hasConcept C121608353 @default.
• W2783175942 hasConcept C126322002 @default.
• W2783175942 hasConcept C127848430 @default.
• W2783175942 hasConcept C143065580 @default.
• W2783175942 hasConcept C143998085 @default.
• W2783175942 hasConcept C2777334693 @default.
• W2783175942 hasConcept C2908731994 @default.
• W2783175942 hasConcept C2909984355 @default.
• W2783175942 hasConcept C502942594 @default.
• W2783175942 hasConcept C54355233 @default.
• W2783175942 hasConcept C71924100 @default.
• W2783175942 hasConcept C86803240 @default.
• W2783175942 hasConceptScore W2783175942C104317684 @default.
• W2783175942 hasConceptScore W2783175942C121608353 @default.
• W2783175942 hasConceptScore W2783175942C126322002 @default.
• W2783175942 hasConceptScore W2783175942C127848430 @default.
• W2783175942 hasConceptScore W2783175942C143065580 @default.
• W2783175942 hasConceptScore W2783175942C143998085 @default.

• next